Literature DB >> 19632107

Peptides in the treatment of AIDS.

Fred Naider1, Jacob Anglister.   

Abstract

Fusion of HIV-1 and target cells is mediated by the envelope protein gp41 that undergoes a series of conformational changes during the process of infection. Knowledge of the structural biology of gp41 allows the design of potent peptide inhibitors that prevent the virus from entering lymphocytes and macrophages. The design of such inhibitors is the subject of this review.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19632107      PMCID： PMC2763535          DOI： 10.1016/j.sbi.2009.07.003

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN： 0959-440X            Impact factor:   6.809


  52 in total

1.  Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.

Authors:  D M Eckert; V N Malashkevich; L H Hong; P A Carr; P S Kim
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Authors:  Elisabetta Bianchi; Marco Finotto; Paolo Ingallinella; Renee Hrin; Anthony V Carella; Xiaoli S Hou; William A Schleif; Michael D Miller; Romas Geleziunas; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

Review 3.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

4.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

Authors:  D C Chan; C T Chutkowski; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41.

Authors:  M Caffrey; M Cai; J Kaufman; S J Stahl; P T Wingfield; D G Covell; A M Gronenborn; G M Clore
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

6.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

8.  The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20.

Authors:  Zohar Biron; Sanjay Khare; Sabine R Quadt; Yehezkiel Hayek; Fred Naider; Jacob Anglister
Journal:  Biochemistry       Date:  2005-10-18       Impact factor: 3.162

9.  Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

Authors:  Hongmei Mo; Alex K Konstantinidis; Kent D Stewart; Tatyana Dekhtyar; Teresa Ng; Kerry Swift; Edmund D Matayoshi; Warren Kati; William Kohlbrenner; Akhteruzzaman Molla
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

10.  Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Authors:  Shuwen Liu; Hong Lu; Jinkui Niu; Yujia Xu; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2005-01-07       Impact factor: 5.157
View more
  36 in total

Review 1.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

2.  Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.

Authors:  Huihui Chong; Xue Yao; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

3.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

4.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

5.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

6.  Evaluation of ligand-based NMR screening methods to characterize small molecule binding to HIV-1 glycoprotein-41.

Authors:  Shidong Chu; Guangyan Zhou; Miriam Gochin
Journal:  Org Biomol Chem       Date:  2017-06-07       Impact factor: 3.876

7.  The M-T hook structure is critical for design of HIV-1 fusion inhibitors.

Authors:  Huihui Chong; Xue Yao; Jianping Sun; Zonglin Qiu; Meng Zhang; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

8.  Prediction of the interaction of HIV-1 integrase and its dicaffeoylquinic acid inhibitor through molecular modeling approach.

Authors:  Zengjian Hu; Dagang Chen; Lanxiang Dong; W M Southerland
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

9.  The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.

Authors:  Adi Moseri; Zohar Biron; Boris Arshava; Tali Scherf; Fred Naider; Jacob Anglister
Journal:  FEBS J       Date:  2015-10-22       Impact factor: 5.542

10.  HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes.

Authors:  Pedro M Matos; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.